新型Castor弓部分支装置在欧洲的初步多中心经验:中期结果研究
波兰5个血管外科中心纳入21例需在2区锚定的主动脉病变患者,评估Castor覆膜支架的中期结果。技术成功19例(90.48%),随访平均14个月(范围1-40个月),2例因I型内漏和左锁骨下动脉分支血栓各需再干预。作者认为Castor装置易于使用且中期结果良好,是TEVAR中需左锁骨下动脉血运重建时的优良选择。
要点
- 21例患者中20例(95.24%)存活,技术成功19例(90.48%)。
- 术后I型内漏2例(9.52%),鸟嘴征2例(9.52%)。
- 随访平均14个月(范围1-40个月),2例分别因I型内漏和左锁骨下动脉分支血栓再干预。
核心结论
- 作者认为Castor装置易于使用且中期结果良好,是TEVAR中需左锁骨下动脉血运重建时的优良选择。
研究设计与样本
- 来自波兰5个血管外科中心的21例患者,包括亚急性期B型主动脉夹层(TBAD)且至少1个经典囊性退变危险因素、胸主动脉瘤(TAA)超过5.5 cm、亚急性期壁内血肿(IMH)和穿透性主动脉溃疡(PAU)且至少1个血管内治疗指征者。
- 研究重点描述主动脉弓结构及TBAD囊性退变因素,报告Castor装置植入后早期并发症、远期并发症和再干预情况。
主要发现
- 20例(95.24%)患者存活,19例(90.48%)技术成功(Castor装置植入位置正确、左锁骨下动脉分支通畅且无内漏)。
- 术后I型内漏2例(9.52%,技术成功未达成),鸟嘴征2例(9.52%)。
- 另观察入路部位血肿1例、假性动脉瘤1例、入路髂动脉破裂需植入Viabahn装置1例。
- 随访期间(平均14个月,范围1-40个月),1例因I型内漏再干预,1例因左锁骨下动脉(LSA)分支血栓再干预。
- 2例因内脏主动脉不良重塑和快速动脉瘤形成需后续分支血管内主动脉修复,与Castor结果无关。
临床怎么用
- 作者认为Castor装置是TEVAR中需左锁骨下动脉血运重建时的优良选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Published reports demonstrate that the use of Castor stent-graft is a promising treatment of aortic pathologies with the need to land in zone 2. However, there is a lack of publications on the medium-term results of Castor in the European population. This research evaluates the mid-term results of the Castor stent-graft in several Polish centers for the treatment of aortic pathologies and enriches the current knowledge of Castor stent-grafts. MATERIAL AND METHODS: Twenty-one patients from 5 polish vascular surgery centers in subacute phase of type B aortic dissection (TBAD) with at least 1 classic risk factor of aneurysmatic degeneration, thoracic aortic aneurysms (TAAs) exceeding 5.5 cm, subacute phase of intramural hematomas (IMHs) and penetrating aortic ulcerations (PAUs) with at least 1 indication to endovascular treatment. Structure of the aortic arch and factors of aneurysmal degeneration for TBAD were highlighted. Early complications, long-term complications, and reinterventions after Castor device implantation are reported in the study. RESULTS: Twenty (95.24%) patients survived, of which a technical success involving implantation of the Castor device in the correct location with a patent branch for the left subclavian artery, and no endoleaks were noted in 19 (90.48%) patients. After the procedure, there were 2 (9.52%) cases of type I endoleak (in which technical success was not achieved) and 2 (9.52%) cases of bird beak. In addition, 1 case of access site hematoma, 1 case of pseudoaneurysm, and 1 case of access iliac artery rupture requiring implantation of a Viabahn device were observed. During the follow-up period (mean 14 months; range = 1-40 months), 1 patient required reintervention due to type I endoleak and 1 patient due to left subclavian artery (LSA) branch thrombosis. Two patients required subsequent branched endovascular aortic repair procedure due to unfavorable remodeling and fast aneurysm formation in visceral aorta, regardless of Castor results. CONCLUSION: The Castor device is an easy-to-use stent-graft with good medium-term results. It is an excellent option in cases requiring LSA revascularization during TEVAR.Clinical ImpactIn this study, we investigate the medium-term results of the Castor stent graft in patients with type B aortic dissection, thoracic aortic aneurysm, intramural hematoma and penetrating aortic ulceration. The medium-term results of treatment with the Castor device are not yet well studied. Currently, there are only a small number of publications on the safety, complications and success of Castor device implantation.
引用
- Żołnierczuk M, Rynio P, Rybicka A, et al. Initial Multicenter Experience With the New Castor Arch Branched Device in Europe: A Middle-term Results Study. J Endovasc Ther. 2024. PMID: 39665395. doi:10.1177/15266028241304307
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。